These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16198977)

  • 1. Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer.
    Szarewski A
    Lancet Oncol; 2005 Oct; 6(10):736-7; author reply 737. PubMed ID: 16198977
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer.
    Shapiro S
    Lancet Oncol; 2005 Oct; 6(10):736; author reply 737. PubMed ID: 16198976
    [No Abstract]   [Full Text] [Related]  

  • 3. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment.
    Cogliano V; Grosse Y; Baan R; Straif K; Secretan B; El Ghissassi F;
    Lancet Oncol; 2005 Aug; 6(8):552-3. PubMed ID: 16094770
    [No Abstract]   [Full Text] [Related]  

  • 4. [International consensus on combined oral estrogen-progestagen contraception and cardiovascular diseases].
    Gynecol Obstet Fertil; 2000 Feb; 28(2):155-62. PubMed ID: 10758591
    [No Abstract]   [Full Text] [Related]  

  • 5. Genital cancer and oral contraceptives. The good news!
    Skouby SO
    Eur J Contracept Reprod Health Care; 2008 Dec; 13(4):327-9. PubMed ID: 19117249
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives and the risk of breast cancer.
    Grant EC
    N Engl J Med; 2002 Oct; 347(18):1448-9; author reply 1448-9. PubMed ID: 12418035
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy. A follow up study].
    Ulrich LS; Wells M; Sturdee DW; Barlow DH; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    Ugeskr Laeger; 2003 Sep; 165(37):3530-2. PubMed ID: 14531356
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of sex steroids on proliferation in normal mammary tissue.
    Söderqvist G
    Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral contraceptives and oral candidiasis].
    Krekeler G; Ochs G; Haderthauer W
    Fortschr Med; 1981 Feb; 99(7):230-2. PubMed ID: 7216106
    [No Abstract]   [Full Text] [Related]  

  • 11. [Benefits and risk of the modern combined hormonal contraception].
    Fait T; Nouzová K; Sýkorová P; Fanta M; Vrablík M; Skrenková J
    Cas Lek Cesk; 2005; 144(4):238-44. PubMed ID: 15945482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Breast cancer and the use of hormones around menopause].
    Boukes FS; Groeneveld FP; Goudswaard AN
    Ned Tijdschr Geneeskd; 2004 Jun; 148(23):1170. PubMed ID: 15211974
    [No Abstract]   [Full Text] [Related]  

  • 13. 10. Cancers attributable to exposure to hormones in the UK in 2010.
    Parkin DM
    Br J Cancer; 2011 Dec; 105 Suppl 2(Suppl 2):S42-8. PubMed ID: 22158320
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms of hormonal therapy related thrombosis.
    Sandset PM
    Thromb Res; 2013 Jan; 131 Suppl 1():S4-7. PubMed ID: 23452740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amenorrhea after hormonal contraception. Prophylaxis, findings and therapy].
    Kunz J
    Gynakol Rundsch; 1976; 16(1):47-64. PubMed ID: 986984
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral contraceptives and venous thromboembolic events.
    Shulman LP; Goldzieher JW; Minkin MJ; Sulak PJ; Thorneycroft I
    J Reprod Med; 2003 Apr; 48(4):306-7. PubMed ID: 12747000
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hormonal contraceptives].
    Hamerlynck JV
    Ned Tijdschr Geneeskd; 1987 Dec; 131(50):2286-90. PubMed ID: 3696265
    [No Abstract]   [Full Text] [Related]  

  • 18. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
    Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):143-7. PubMed ID: 23578274
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.
    Gomes MP; Deitcher SR
    Arch Intern Med; 2004 Oct; 164(18):1965-76. PubMed ID: 15477430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral contraceptives: update].
    Fugère P
    Union Med Can; 1983 Feb; 112(2):109-12. PubMed ID: 6845551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.